Wordt geladen...
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging hematologic malignancy with dismal outcomes. With a median age of ∼70 years, the majority of patients with BPDCN have experienced historically suboptimal responses with intensive chemotherapy regimens. The majo...
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448601/ https://ncbi.nlm.nih.gov/pubmed/32841341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000173 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|